Premium
Hepatoblastoma, cisplatin, and ototoxicity
Author(s) -
Sullivan Michael J.
Publication year - 2009
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.24668
Subject(s) - ototoxicity , medicine , hepatoblastoma , amifostine , cisplatin , hearing loss , sodium thiosulfate , randomized controlled trial , oncology , toxicity , audiology , intensive care medicine , chemotherapy , inorganic chemistry , chemistry
Young infants with hepatoblastoma now have an excellent chance of cure, but many will be left with significant cisplatin‐related hearing loss, which may impair their language and social development and may affect later learning with a lifetime of hearing loss. A report from the Children's Oncology Group of a randomized trial of amifostine for the prevention of platinum‐related toxicity in infants with hepatoblastoma demonstrated that amifostine has no benefit in reducing cisplatin ototoxicity. Several new agents, such as sodium thiosulfate, currently are entering clinical trials as otoprotectants; however, as the goal for some childhood malignancies shifts from disease cure to enhancing the quality of long‐term survival, there is a need to ensure that the design and conduct of cancer‐control trials are as rigorous as those directed toward curing disease.